Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer

IMPORTANCE: Biologic therapy (BT) (eg, bevacizumab or cetuximab) is increasingly used to treat metastatic colorectal cancer (mCRC). Recent investigations have suggested that right- or left-sided primary tumor origin affects survival and response to BT. OBJECTIVE: To evaluate the association of tumor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Surg
Auteurs principaux: Aljehani, Mayada A., Morgan, John W., Guthrie, Laurel A., Jabo, Brice, Ramadan, Majed, Bahjri, Khaled, Lum, Sharon S., Selleck, Matthew, Reeves, Mark E., Garberoglio, Carlos, Senthil, Maheswari
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2017
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833618/
https://ncbi.nlm.nih.gov/pubmed/28975237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamasurg.2017.3466
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires